Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics
Abstract The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of mul...
Main Authors: | Hua Qin, Andong Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-06-01
|
Series: | Protein & Cell |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13238-020-00738-2 |
Similar Items
-
Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives
by: Silvia Fernández-Francos, et al.
Published: (2021-07-01) -
Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment
by: Wendi Wang, et al.
Published: (2021-05-01) -
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
by: Seyed-Mohammad Reza Hashemian, et al.
Published: (2021-01-01) -
Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options
by: Trushil G. Shah, et al.
Published: (2019-09-01) -
Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
by: Amy L. Xu, et al.
Published: (2019-10-01)